MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings

EQS-News: MorphoSys AG


/ Key word: Miscellaneous





MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings






11.05.2023 / 18:39... | May 11, 2023

Related Keywords

Germany ,Illinois ,United States ,Boston ,Massachusetts ,Chicago ,Planegg ,Bayern ,American ,Julia Neugebauer ,Eamonn Nolan ,Tim Demuth ,Thomas Biegi ,Constellation Pharmaceuticals Inc ,European Hematology Association ,Nasdaq ,American Society Of Hematology Annual Meeting ,Xencor Inc ,American Society Of Clinical Oncology ,Drug Administration ,Linkedin ,Exchange Commission ,Development Officer ,Twitter ,American Association For Cancer Research Annual Meeting ,Sys Highlights Potential ,Late Stage Oncology Pipeline ,American Society ,Clinical Oncology ,Annual Meeting ,Hybrid Congress ,Morphosys Chief Research ,American Association ,Cancer Research Annual Meeting ,High Risk Essential Thrombocythemia Refractory ,Preliminary Results From ,Advanced Solid Tumors ,Hematologic Malignancies ,Preliminary Phase ,Subgroup Analysis ,Refractory Diffuse Largeb Cell ,Combined With Ruxolitinib ,Patients With ,Final Results ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Medication Guide ,Prescribing Information ,Patient Information ,Important Safety ,Morphosy Annual Report ,Morphosys Ag Stock Exchange ,News ,Information ,Press Release ,Morphosys ,Key ,Highlights ,Potential ,F ,Its ,O ,Ncology ,Pipeline ,It ,023 ,Disco ,End ,Ha ,Nnual ,Eetings Mor De0006632003 ,